Related Experiment Video
Updated: Nov 4, 2025
05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
7.7K
Dasiglucagon: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|May 28, 2021
Summary
Dasiglucagon (Zegalogue) is a new antihypoglycaemic treatment for severe hypoglycemia in patients with diabetes. This glucagon analogue is now available in the USA as an autoinjector or prefilled syringe.
Area of Science:
- Pharmacology
- Endocrinology
- Diabetes Management
Background:
- Hypoglycemia is a common complication in diabetes management.
- Existing treatments for severe hypoglycemia have limitations.
- Dasiglucagon offers a novel therapeutic approach.
Purpose of the Study:
- To summarize the development milestones of dasiglucagon.
- To highlight the regulatory approval process for hypoglycemia treatment.
- To provide an overview of dasiglucagon's therapeutic potential.
Main Methods:
- Review of preclinical and clinical development data.
- Analysis of regulatory submission and approval timelines.
- Pharmacological characterization of dasiglucagon as a glucagon analogue.
Main Results:
- Dasiglucagon development progressed through key clinical trials.
- The U.S. Food and Drug Administration (FDA) approved dasiglucagon in March 2021.
- The approval was for the treatment of severe hypoglycemia in patients aged 6 years and above with diabetes.
Conclusions:
- Dasiglucagon represents a significant advancement in hypoglycemia treatment.
- The drug's availability offers a new option for patients and healthcare providers.
- Successful development and approval underscore its therapeutic value.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
513
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
513
01:06Oral Hypoglycemic Agents: Glinides
345
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
345
01:23Dipeptidyl Peptidase 4 Inhibitors
316
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
316
01:15Hypoglycemia and Glucagon
498
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
498
01:26FDA Approved Drugs: Changes to Approved Drugs
38
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
38
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
345
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
345